BioSpace News Archive

Technavio has announced its latest market research report titled global orthopedic 3D printing devices market 2019-2023.

Competition Recognizes Employers with Exceptional HR Programs and Forward-Thinking Workplace Policies

CVS Health (NYSE: CVS) today announced Transform Oncology Care™, anchored on a first-of-its-kind precision medicine strategy for payors

Neogen Corporation (NASDAQ: NEOG) announced today that it has developed a quick and simple lateral flow test for ergot alkaloids, which are natural toxins produced by a fungus that commonly infects rye and wheat. Ingestion of ergot alkaloids can cause ergotism, a dangerous disease in humans and animals.

Shineco, Inc. announced that the Company, through its subsidiary Shineco China Hemp Technology Co., Ltd., has award an certificate from Trade & Association on November 29, 2019 to jointly establish industry hemp comprehensive utilization park in China.

Led by Chief Executive Officer Howard Federoff, M.D., Ph.D., Former Vice Chancellor for Health Affairs and Chief Executive Officer of the University of California Irvine Health System

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that KEYTRUDA, Merck’s anti-PD-1 therapy, showed improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) as monotherapy for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC) whose tumors expressed PD-L1 (tumor proportion score [TPS] ≥1%), regardless of KRAS mutational status.

Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a poster presentation at the 58th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), in Orlando, FL.

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it completed a Type B multidisciplinary meeting with the U.S. Food and Drug Administration (FDA) to discuss the proposed contents of a Biologics License Application (BLA) for PRV-031 (teplizumab) for the prevention or delay of type 1 diabetes (T1D) in individuals at-risk of developing T1D

Entering into a new decade, boards and C-suite leaders around the globe are concerned with the escalating competition for specialized talent, their organizations’ culture and the ability to advance their digital maturity and embrace the transformative opportunities of technology.